144 related articles for article (PubMed ID: 33209110)
1. Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone.
Murray NP; Aedo S; Villalon R; Albarran V; Orrego S; Guzman E
Ecancermedicalscience; 2020; 14():1119. PubMed ID: 33209110
[TBL] [Abstract][Full Text] [Related]
2. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
[TBL] [Abstract][Full Text] [Related]
3. Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
Murray NP; Villalon R; Orrego S; Guzman E
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2391-2397. PubMed ID: 34452551
[TBL] [Abstract][Full Text] [Related]
4. The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.
Murray NP; Villalon R; Orrego S; Guzman E
Colorectal Dis; 2021 Apr; 23(4):805-813. PubMed ID: 33169474
[TBL] [Abstract][Full Text] [Related]
5. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
[TBL] [Abstract][Full Text] [Related]
6. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
[TBL] [Abstract][Full Text] [Related]
7. The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Ecancermedicalscience; 2020; 14():1063. PubMed ID: 32728379
[TBL] [Abstract][Full Text] [Related]
8. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
Murray NP; Villalon R; Hartmann D; Rodriguez MP; Aedo S
Colorectal Dis; 2021 Nov; 23(11):2879-2893. PubMed ID: 34473913
[TBL] [Abstract][Full Text] [Related]
9. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
[TBL] [Abstract][Full Text] [Related]
10. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
[TBL] [Abstract][Full Text] [Related]
11. The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.
Murray NP; Villalon R; Aedo S; Hartmann D; Rodriguez MP
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3373-3379. PubMed ID: 37898840
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of laparoscopic resection of colorectal carcinoma from the viewpoint of molecular biology.
Skrovina M; Duda M; Srovnal J; Bartos J; Radova L; Hajduch M; Soumarova R
Wideochir Inne Tech Maloinwazyjne; 2012 Mar; 7(1):19-26. PubMed ID: 23255996
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
[TBL] [Abstract][Full Text] [Related]
14. The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.
Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Turk J Urol; 2020 Sep; 46(5):360-366. PubMed ID: 32707032
[TBL] [Abstract][Full Text] [Related]
15. DTCs in breast cancer: clinical research and practice.
Janni W; Rack B; Kasprowicz N; Scholz C; Hepp P
Recent Results Cancer Res; 2012; 195():173-8. PubMed ID: 22527504
[TBL] [Abstract][Full Text] [Related]
16. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
17. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
[TBL] [Abstract][Full Text] [Related]
18. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
20. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
